JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.66 -1.19

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.63

Максимум

1.72

Ключови измерители
By Trading Economics
Приходи	13M -43M
Марж на печалбата	-2,190.837
Служители	171
EBITDA	17M -42M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+59.52% upside

Дивиденти
By Dow Jones
Следващи печалби	6.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	6.8M 111M
Предишно отваряне	2.85
Предишно затваряне	1.66

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.11.2025 г., 21:44 ч. UTC

Печалби

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3.11.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3.11.2025 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3.11.2025 г., 23:28 ч. UTC

Печалби

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3.11.2025 г., 23:24 ч. UTC

Печалби

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3.11.2025 г., 23:14 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Global Equities Roundup: Market Talk

3.11.2025 г., 23:14 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3.11.2025 г., 23:12 ч. UTC

Печалби

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3.11.2025 г., 23:09 ч. UTC

Печалби

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3.11.2025 г., 23:09 ч. UTC

Печалби

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3.11.2025 г., 23:09 ч. UTC

Печалби

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3.11.2025 г., 23:06 ч. UTC

Пазарно говорене

Печалби

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3.11.2025 г., 22:36 ч. UTC

Пазарно говорене

Печалби

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3.11.2025 г., 22:31 ч. UTC

Печалби

Franco-Nevada 3Q EPS $1.49 >FNV

3.11.2025 г., 22:31 ч. UTC

Печалби

Franco-Nevada 3Q Rev $487.7M >FNV

3.11.2025 г., 22:24 ч. UTC

Пазарно говорене

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3.11.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

Starbucks Agrees to Sell Stake in China Business -- WSJ

3.11.2025 г., 21:59 ч. UTC

Пазарно говорене

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3.11.2025 г., 21:54 ч. UTC

Пазарно говорене

Печалби

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3.11.2025 г., 21:54 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

3.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

3.11.2025 г., 21:49 ч. UTC

Печалби

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3.11.2025 г., 21:40 ч. UTC

Печалби

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3.11.2025 г., 21:31 ч. UTC

Пазарно говорене

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3.11.2025 г., 21:19 ч. UTC

Печалби

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3.11.2025 г., 21:11 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3.11.2025 г., 21:11 ч. UTC

Печалби

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3.11.2025 г., 21:07 ч. UTC

Печалби

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3.11.2025 г., 21:05 ч. UTC

Печалби

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3.11.2025 г., 21:05 ч. UTC

Печалби

Palantir Technologies 3Q Net $475.6M >PLTR

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

59.52% нагоре

12-месечна прогноза

Среден 2.68 USD 59.52%

Висок 4 USD

Нисък 1.7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.